LGM
PTGX icon

Logos Global Management’s Protagonist Therapeutics PTGX Stock Holding History

Logos Global Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-300,000
Closed -$19.9M – 81
2025
Q3 		$19.9M Buy
+300,000
New +$17.1M 1.79% 25
2022
Q1 		– Sell
-250,000
Closed -$8.55M – 60
2021
Q4 		$8.55M Buy
+250,000
New +$7.9M 0.88% 29

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Logos Global Management's PTGX Position: Q4 2025 in Review

Logos Global Management sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 300,000 shares — an estimated $19.9M sold.

Logos Global Management first reported a position in PTGX in Q4 2021 and held it in 2 quarters. The position peaked at $19.9M in Q3 2025. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Logos Global Management reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Logos Global Management sold 300,000 Protagonist Therapeutics shares in Q4 2025, an estimated $19.9M.
  • Logos Global Management first reported a position in Protagonist Therapeutics in Q4 2021 and held it in 2 quarters.
  • Logos Global Management's Protagonist Therapeutics position peaked at $19.9M in Q3 2025.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Logos Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.